Natural killer cell expressing anti-cotinine chimeric antigen receptor
US11707486B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 5, 2019 |
| Grant date | Jul 25, 2023 |
| Priority date | — |
| Expiry date | Apr 20, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.